Education
About Us
Working with TipRanks
Follow Us
Enliven Therapeutics (ELVN)
NASDAQ:ELVN
Total Valuation
Enliven Therapeutics has a market cap or net worth of $1.18B. The enterprise value is $555.10M.
Market Cap$1.18B
Enterprise Value$555.10M
Share Statistics
Enliven Therapeutics has 59,235,546 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding59,235,546
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Enliven Therapeutics’s return on equity (ROE) is -0.29 and return on invested capital (ROIC) is -33.66%.
Return on Equity (ROE)-0.29
Return on Assets (ROA)-0.27
Return on Invested Capital (ROIC)-33.66%
Return on Capital Employed (ROCE)-0.34
Revenue Per Employee0.00
Profits Per Employee-1.44M
Employee Count62
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Enliven Therapeutics is ―. Enliven Therapeutics’s PEG ratio is ―.
PE Ratio―
PS Ratio―
PB Ratio―
Price to Fair Value3.42
Price to FCF―
Price to Operating Cash Flow-14.65
PEG Ratio―
Income Statement
In the last 12 months, Enliven Therapeutics had revenue of 0.00 and earned -89.02M in profits. Earnings per share was -1.89.
Revenue0.00
Gross Profit-317.00K
Operating Income-104.55M
Pretax Income-88.79M
Net Income-89.02M
EBITDA-88.47M
Earnings Per Share (EPS)-1.89
Cash Flow
In the last 12 months, operating cash flow was -70.58M and capital expenditures -181.00K, giving a free cash flow of -70.76M billion.
Operating Cash Flow-70.58M
Free Cash Flow-70.76M
Free Cash Flow per Share-1.19
Dividends & Yields
Enliven Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.40
52-Week Price Change-9.07%
50-Day Moving Average20.60
200-Day Moving Average21.15
Relative Strength Index (RSI)56.87
Average Volume (3m)381.31K
Important Dates
Enliven Therapeutics upcoming earnings date is Nov 6, 2025, Before Open (Confirmed).
Last Earnings DateAug 13, 2025
Next Earnings DateNov 6, 2025
Ex-Dividend Date―
Financial Position
Enliven Therapeutics as a current ratio of 19.99, with Debt / Equity ratio of 0.08%
Current Ratio19.99
Quick Ratio19.99
Debt to Market Cap0.00
Net Debt to EBITDA1.40
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Enliven Therapeutics has paid -232.00K in taxes.
Income Tax-232.00K
Effective Tax Rate<0.01
Enterprise Valuation
Enliven Therapeutics EV to EBITDA ratio is -10.57, with an EV/FCF ratio of -12.77.
EV to Sales0.00
EV to EBITDA-10.57
EV to Free Cash Flow-12.77
EV to Operating Cash Flow-12.77
Balance Sheet
Enliven Therapeutics has $490.50M in cash and marketable securities with $376.00K in debt, giving a net cash position of -$490.13M billion.
Cash & Marketable Securities$490.50M
Total Debt$376.00K
Net Cash-$490.13M
Net Cash Per Share-$8.27
Tangible Book Value Per Share$6.58
Margins
Gross margin is -24.37%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin-24.37%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Enliven Therapeutics is $42.29, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$42.29
Price Target Upside102.83% Upside
Analyst ConsensusStrong Buy
Analyst Count8
Revenue Growth Forecast―
EPS Growth Forecast-3.53%